A 44% objective response rate in heavily pretreated ovarian cancer patients is the number PMV Pharmaceuticals is betting its regulatory future on. Updated interim data from the Phase 2 pivotal portion of the PYNNACLE trial, with a May 14, 2026 data cutoff, show rezatapopt monotherapy delivering that response rate in patients whose tumors carry a TP53 Y220C mutation, a genetically defined subset that has historically had few targeted options and is typically managed with chemotherapy until progression. That figure, in a single-arm registrational cohort, is the direct evidence base PMV will carry into an FDA discussion about whether this data package supports accelerated approval.
The clinical logic here is unusually clean for an oncology program. Rezatapopt is an orally available small molecule that binds a hydrophobic pocket created specifically by the Y220C mutation, refolding misshapen p53 protein back toward functional conformation. Because the drug’s target is the mutation itself rather than a downstream pathway, patient selection is binary: tumors either carry Y220C or they do not. That precision cuts enrollment noise and, critically, gives regulators a biomarker-defined population in which to interpret single-arm response data without a randomized comparator arm. The registrational design across five tumor-type cohorts in PYNNACLE reflects PMV’s read that the FDA is receptive to this framework in genomically selected populations.
What the interim data do not yet resolve is durability. Response rate in a snapshot dataset tells you tumors shrank; it does not tell you for how long. The ovarian cancer cohort in a single-arm trial will face scrutiny on progression-free and overall survival curves before any label claim about clinical benefit can be made definitive. PMV is betting that the Y220C selection is tight enough, and the unmet need deep enough in this line of therapy, to clear an accelerated pathway on response alone while confirmatory data mature. That is a reasonable bet, but it is still a bet.
The number to track from here is not the response rate itself but the duration of response in the May cutoff dataset. If the median duration of response in the ovarian cohort holds above six months in the full data package submitted to FDA, the accelerated approval argument becomes substantially harder to dismiss.
Source link: https://www.sec.gov/Archives/edgar/data/1699382/000119312526376723/d441751d8k.htm
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
